Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Metabolic Drivers and Bioenergetic Components of Neurodegenerative Disease reviews how the different aspects of metabolic dysfunction and consequent pathology associated with neurodegenerative diseases, including Alzheimer's and Parkinson's, can be targeted by novel treatment approaches. Topics covered include Cellular Senescence in Aging and Age-Related Disorders: Implications for Neurodegenerative Diseases; Repurposing GLP1 agonists for Neurodegenerative Diseases; Ketotherapeutics for Neurodegenerative Diseases; Enhancing Mitophagy as a Therapeutic Approach for Neurodegenerative Diseases;…mehr
Metabolic Drivers and Bioenergetic Components of Neurodegenerative Disease reviews how the different aspects of metabolic dysfunction and consequent pathology associated with neurodegenerative diseases, including Alzheimer's and Parkinson's, can be targeted by novel treatment approaches. Topics covered include Cellular Senescence in Aging and Age-Related Disorders: Implications for Neurodegenerative Diseases; Repurposing GLP1 agonists for Neurodegenerative Diseases; Ketotherapeutics for Neurodegenerative Diseases; Enhancing Mitophagy as a Therapeutic Approach for Neurodegenerative Diseases; Harnessing Neurogenesis in the Adult Brain - A Role in Type 2 Diabetes Mellitus and Alzheimer's disease; and much more.
Summarizes the impact of the metabolic hypothesis on underlying mechanisms of neurodegenerative diseases
Presents novel, potential treatment strategies based on the metabolic hypothesis for neurodegenerative diseases
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Autorenporträt
Grazyna Söderbom, PhD is founder of Klipspringer AB. She received her BSc 1st Class Hons in Pharmacology & Toxicology from King's College, London and PhD in Neuroscience from the University of London. She spent one year of her undergraduate studies investigating the role of the AT2-receptor subtype at Ciba-Geigy under the tutelage of Dr Marc de Gasparo. As a Wellcome Trust PhD Scholar in Prof. Peter Jenner's Neurodegenerative Research Group, Grazyna focused on the aetiology of Parkinson's disease, specifically the relevance of antioxidant enzymes in the basal ganglia and Parkinson's pathogenesis. After working as a Post-Doctoral Research Fellow at the Clinical Age Research Unit at King's College Hospital, Grazyna joined Zeneca/AstraZeneca Pharmaceuticals, which included five years as Global Brand Manager in Cardiovascular Medicine in Sweden. She was involved in the global marketing and communications behind the antihypertensive Atacand® and the launch of Atacand Plus®. Having disc
overed a strong interest in strategic medical communications, Grazyna launched Klipspringer in 2013, which specializes in scientific, medical and strategic writing and consultation for Academia, Bio-Pharma and beyond. Grazyna is passionate about "all things science?, especially neuroscience, and the effective sharing of scientific knowledge to all levels of audiences. She has published scientific research of her own and now supports others in their scientific and medical communications. Grazyna is particularly interested in the potential implications of the link between metabolic disease and neurodegenerative disorders.
Inhaltsangabe
1. Dysregulation of metabolic flexibility: The impact of mTOR on autophagy in neurodegenerative diseases Kenneth Maiese 2. Antidiabetic drugs for Alzheimer´s and Parkinson´s diseases: Repurposing insulin, metformin and thiazolidinediones Susana Cardoso and Paula I. Moreira 3. Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases Christian Hölscher 4. Repurposing GLP1 agonists for neurodegenerative diseases Ioanna Markaki, Kristian Winther, Sergiu-Bogdan Catrina and Per Svenningsson 5. A role for Sodium Glucose coTransporter 2 inhibitors (SGLT2i) in the treatment of Alzheimer's disease? Russell Esterline, Jan Oscarsson and Jeffrey Burns 6. Ketotherapeutics for neurodegenerative diseases Nicholas G. Norwitz, Javier Gilbert Jaramillo, Kieran Clarke and Adrian Soto 7. Enhancing mitophagy as a therapeutic approach for neurodegenerative diseases Yahyah Aman, Brent Ryan, Silje Bøen Torsetnes, Anne-Brita Knapskog, Leiv Otto Watne, William A. McEwan and Evandro Fei Fang 8. Cellular senescence in aging and age-related disorders: Implications for neurodegenerative diseases Erin O. Wissler Gerdes, Yi Zhu, Bettina M. Weigand, Utkarsh Tripathi, Terence C. Burns, Tamar Tchkonia and James L. Kirkland 9. Harnessing neurogenesis in the adult brain-A role in type-2-diabetes mellitus and Alzheimer's disease Orly Lazarov, Richard D. Minshall and Marcelo G. Bonini 10. Hormesis: A therapeutic strategic approach in the treatment of neurodegenerative disease Edward J. Calabrese, Mark P. Mattson, Gaurav Dhawan, Rachna Kapoor, Vittorio Calabrese and James Giordano
1. Dysregulation of metabolic flexibility: The impact of mTOR on autophagy in neurodegenerative diseases Kenneth Maiese 2. Antidiabetic drugs for Alzheimer´s and Parkinson´s diseases: Repurposing insulin, metformin and thiazolidinediones Susana Cardoso and Paula I. Moreira 3. Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases Christian Hölscher 4. Repurposing GLP1 agonists for neurodegenerative diseases Ioanna Markaki, Kristian Winther, Sergiu-Bogdan Catrina and Per Svenningsson 5. A role for Sodium Glucose coTransporter 2 inhibitors (SGLT2i) in the treatment of Alzheimer's disease? Russell Esterline, Jan Oscarsson and Jeffrey Burns 6. Ketotherapeutics for neurodegenerative diseases Nicholas G. Norwitz, Javier Gilbert Jaramillo, Kieran Clarke and Adrian Soto 7. Enhancing mitophagy as a therapeutic approach for neurodegenerative diseases Yahyah Aman, Brent Ryan, Silje Bøen Torsetnes, Anne-Brita Knapskog, Leiv Otto Watne, William A. McEwan and Evandro Fei Fang 8. Cellular senescence in aging and age-related disorders: Implications for neurodegenerative diseases Erin O. Wissler Gerdes, Yi Zhu, Bettina M. Weigand, Utkarsh Tripathi, Terence C. Burns, Tamar Tchkonia and James L. Kirkland 9. Harnessing neurogenesis in the adult brain-A role in type-2-diabetes mellitus and Alzheimer's disease Orly Lazarov, Richard D. Minshall and Marcelo G. Bonini 10. Hormesis: A therapeutic strategic approach in the treatment of neurodegenerative disease Edward J. Calabrese, Mark P. Mattson, Gaurav Dhawan, Rachna Kapoor, Vittorio Calabrese and James Giordano
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826